arrow
S

Stephen Johnston

royal marsden nhs foundation trust
H指数:62
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer

I期/II期H3B-6545在局部晚期/转移性雌激素受体阳性、HER2阴性乳腺癌女性患者中的研究

2025-08-290
OAAI
Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer
2024-10-181
OAAI
Results from a pilot study exploring ctDNA detection using a tumor-informed assay in the monarchE trial of adjuvant abemaciclib with endocrine therapy in HR+, HER2-, node-positive, high-risk early breast cancer
2024-05-020
PRE
Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial
2024-05-021
PRE
MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2-advanced breast cancer
2024-05-022
PRE
Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer
2024-03-015
OAAI
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer

Abemaciclib单独或与内分泌治疗在晚期乳腺癌中循环肿瘤DNA的基线和获得性基因组改变的前景

2023-10-274
OAAI
Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes
2023-10-0110
OA
Immune cell infiltration associated with poor anti-proliferative response to aromatase inhibitors in postmenopausal women with primary ER-positive HER2-negative breast cancer
2023-03-010
PRE
Low plasma estradiol, low expression of estrogen responsive genes and TP53 mutations are associated with poor anti-proliferative response to aromatase inhibitors
2023-03-010
PRE